Genematrix Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 69

Employees

  • Stock Symbol
  • 109820

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.00
  • (As of Friday Closing)

Genematrix General Information

Description

Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others.

Contact Information

Website
www.genematrix.net
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Korea Bio Park Building B, 8th Floor
  • Sampyeong-dong 694-1, 700 Daewangpangyo-ro, Bundang-gu
  • Seongnam, Gyeonggi 13488
  • South Korea
+82
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
KRX
Vertical(s)
Life Sciences
Corporate Office
  • Korea Bio Park Building B, 8th Floor
  • Sampyeong-dong 694-1, 700 Daewangpangyo-ro, Bundang-gu
  • Seongnam, Gyeonggi 13488
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genematrix Stock Performance

As of 13-Nov-2026, Genematrix’s stock price is $1.00. Its current market cap is $20M with 20M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.00 $0.98 $0.83 - $1.89 $20M 20M 201K

Genematrix Financials Summary

As of 30-Jun-2026, Genematrix has a trailing 12-month revenue of $7.5M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 11,481 25,941 30,016 38,643
Revenue 7,499 7,479 7,343 7,507
EBITDA 52 (1,086) (2,529) (459)
Net Income (131) (1,289) (2,747) (684)
Total Assets 17,883 18,938 19,320 24,330
Total Debt 2,425 2,589 2,522 2,918
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genematrix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genematrix‘s full profile, request access.

Request a free trial

Genematrix Patents

  • 57

    Total Documents Applications and Grants

  • Total Patents Families

  • 17

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Genematrix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025009802-A1 Pcr method for detecting at least two multi-target nucleic acids with single signal Inactive 03-Jul-2023
WO-2023167487-A1 Recombinant expression vector for prevention of sars-cov-2 infection and application thereof Inactive 03-Mar-2022
AU-2022250521-A1 Recombinant chimeric adenoviral vector substituted by knob gene of chimpanzee adenovirus serotype 6, and application thereof Inactive 29-Mar-2021
AU-2022250521-A9 Recombinant chimeric adenoviral vector substituted by knob gene of chimpanzee adenovirus serotype 6, and application thereof Inactive 29-Mar-2021
CA-3213066-A1 Recombinant chimeric adenoviral vector substituted by knob gene of chimpanzee adenovirus serotype 6, and application thereof Pending 29-Mar-2021 C12N15/86
To view Genematrix’s complete patent history, request access »

Genematrix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genematrix Investments (1)

Genematrix’s most recent deal was a Early Stage VC with Barinthus Biotherapeutics for . The deal was made on 20-Dec-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Barinthus Biotherapeutics 20-Dec-2018 Early Stage VC Drug Discovery
To view Genematrix’s complete investments history, request access »

Genematrix ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Genematrix’s complete esg history, request access »

Genematrix Exits (1)

Genematrix’s most recent exit was on 20-Dec-2018 from Barinthus Biotherapeutics. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Barinthus Biotherapeutics 20-Dec-2018 Completed
  • 6 buyers
To view Genematrix’s complete exits history, request access »

Genematrix FAQs

  • When was Genematrix founded?

    Genematrix was founded in 2000.

  • Where is Genematrix headquartered?

    Genematrix is headquartered in Seongnam, South Korea.

  • What is the size of Genematrix?

    Genematrix has 69 total employees.

  • What industry is Genematrix in?

    Genematrix’s primary industry is Pharmaceuticals.

  • Is Genematrix a private or public company?

    Genematrix is a Public company.

  • What is Genematrix’s stock symbol?

    The ticker symbol for Genematrix is 109820.

  • What is the current stock price of Genematrix?

    As of 13-Nov-2026 the stock price of Genematrix is $1.00.

  • What is the current market cap of Genematrix?

    The current market capitalization of Genematrix is $20M.

  • What is Genematrix’s current revenue?

    The trailing twelve month revenue for Genematrix is $7.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process